Treatment of chronic myelogenous leukemia with interferon alfa-2c: response rate and toxicity in a phase II multicenter study. The Austrian Biological Response Modifier (BRM) Study Group.
作者信息
Thaler J, Gastl G, Fluckinger T, Niederwieser D, Huber H, Seewann H, Silly H, Lang A, Abbrederis C, Gadner H
机构信息
Department of Internal Medicine, University of Innsbruck, Austria.
出版信息
Semin Hematol. 1993 Jul;30(3 Suppl 3):17-9.
PMID:8235697
Abstract
摘要
Zotero 插件